drugset / Trial / NCT00431054

Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer

NCT00431054

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find out if a combination treatment of perifosine and docetaxel will help shrink or slow the growth of cancer cells in recurrent ovarian cancer. The safety of this combination treatment will also be studied.

Timeline

Start
2007-02
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject Perifosine Small molecule 50 mg Oral

Indications